Skip to main content

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context

Written by Customer Service on . Posted in Public Companies.

2020 Half-year results:
Stronger financial position and research programs moving forward despite the international contextClinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United StatesAGIR program (Antibiotics against Resistant Infectious Germs): reaching second key milestone generated the payment of €1.5M by BpifranceLaunch of two novel next-generation active substances, including the first extract developed with Hallstar and derived from the fermentation of a Deinove microorganismConsolidated net income: -€4.6M compared to -€5.4M in H1 2019Group cash position:Balance of +€3.2M at June 30, 2020 compared to +€1.1M at December 31, 2019€2M to be received in October: loans granted by Bpifrance (R&D innovation loan) and Société Générale (State guaranteed loan)DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance and the need for next-generation active ingredients serving Health, announces that its Board of Directors has approved the financial statements for the first half of 2020.Charles Woler, Chairman and Chief Executive Officer of DEINOVE, stated: “In the uncertain health and economic context that characterizes 2020, DEINOVE was able to stay the course. Our financial position has improved, and our operating loss has been reduced.  At the same time, we continued our efforts to advance the programs, including the DNV3837 clinical trial, which continued recruiting patients with the support of the investigating physicians, despite the health situation in the United States. Our upstream research programs (AGIR) have also advanced, with completion of the second key milestone, and we continue our efforts to provide the industry with new active substances.Now led by Alexis RIDEAU, our team is resolutely pursuing its activities with three clear objectives: strengthen the company’s presence in the pharmaceutical sector, generate revenues through strategic partnerships in the biotechnology sector, excel in project management in order to control all of our expenses and maintain financial flexibility.“
SYNTHETIC CONSOLIDATED FINANCIAL DATAThe DEINOVE Group’s consolidated financial statements at June 30, 2020 were subject to a limited review by the Group’s statutory auditors, the firm PwC (PricewaterhouseCoopers).PROFIT AND LOSS ACCOUNT

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.